glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Recommendations for the safe and

On a new aerobic metabolite whose production by brain is inhibited by apomorphine, emetine, ergotamine, epinephrine, and menadione

Both involve bioactive peptides, but they work differently, target different goals, and follow very different evidence and regulatory pathways

Vieujean, S

Additionally, a randomized controlled trial revealed that a combination of flavan-3-ols and isoflavones enhanced insulin sensitivity and lipoprotein profiles compared to placebo, further lowering the estimated 10-year CVD risk in women with type 2 diabetes (Peter et al., 2012)

Major semaglutide weight loss trials (STEP 14) did not measure cortisol as a primary or secondary outcome

Meanwhile, as shown in Figure 2C, there was no significant difference in cecal intubation time among the three groups ( p = 0.672)